Abstract
Checkpoint inhibitors and oncolytic vaccine therapy have transformed the management of metastatic melanoma. This article presents the diagnosis and treatment landscape for metastatic melanoma, including clinicopathologic features of the disease, approved and emerging therapeutics, and strategies for integrating contemporary standard-of-care management practices.
